Physician profile
Lawrence B Harkless
NPI 1699882753
$6,951.69
in general payments reported to CMS, 2019-2025
13 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $73.67 · 2021: $68.37 · 2022: $5,589 · 2023: $437 · 2024: $156 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Travel and Lodging: $21.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.78 |
| Travel and Lodging | $21.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $3,270.00 | 2022 | |
| Medline Industries LP | $1,800.00 | 2022 | |
| Stryker Corporation | $407.66 | 2021-2023 | Allograft, Axsos |
| Organogenesis INC. | $381.47 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $257.57 | 2025 | Vibativ, Caldolor |
| Kerecis Limited | $156.26 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Grt US Holding, INC. | $155.42 | 2022 | |
| Mission Medical Distribution, LLC | $143.73 | 2023 | |
| Averitas Pharma INC. | $121.03 | 2023 | Qutenza |
| Melinta Therapeutics, LLC | $116.30 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.97 | 2022 | |
| Philips North America LLC | $53.57 | 2019 | |
| Fusion Orthopedics USA, LLC | $9.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Harkless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.